Amgen (AMGN) announced that the UK’s Medicines and Healthcare products Regulatory Agency has granted marketing authorization for Tepezza as the first therapy specifically licensed for the treatment of adult patients with moderate-to-severe Thyroid Eye Disease. “The marketing authorisation for teprotumumab as the first therapy specifically licensed for Thyroid Eye Disease in the UK marks a step forward for the patient community. TED can negatively affect patients’ lives impacting vision, causing eye pain, making everyday tasks difficult and causing a loss of self-confidence. This authorisation introduces a new alternative treatment option and reinforces Amgen’s commitment to supporting eligible patients with serious, underserved conditions,” said Dr Tony Patrikios, Executive Medical Director, Amgen UK & Ireland.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen price target raised to $280 from $235 at Mizuho
- Amgen’s Mixed Financial Outlook: Strong Q1 Performance but Cautious Future Guidance Leads to Hold Rating
- Amgen’s Strong Financial Performance and Strategic Positioning Earns Buy Rating from Analyst
- Amgen Inc. Reports Strong Growth Amid Challenges
- Amgen price target lowered to $315 from $319 at UBS